News & Videos - PALATIN TECHNOLOGIES INC.

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 PR Newswire CRANBURY, N.J., April 8, 2024 Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), 12-Week Treatment Period Rapid Onset of Efficacy at the 2-Week...

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire CRANBURY, N.J., Feb. 28, 2024 On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met , Statistical Significance (P<0.025) Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025) On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and Secondary Sign Endpoints Not Met PL9643 Demonstrated Superiority Over Vehicle in Multiple Sign Endpoints...

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire CRANBURY, N.J., Feb. 15, 2024 Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February Oral PL8177 Phase 2 Clinical Study in Patients with Ulcerative Colitis – Interim Analysis Expected in 2Q Calendar Year 2024 – Topline Results Expected in 2H...

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 PR Newswire CRANBURY, N.J., Feb. 9, 2024 CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive...

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire CRANBURY, N.J., Feb. 5, 2024 Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1...

Palatin Announces Closing of $10 Million Registered Direct Offering PR Newswire CRANBURY, N.J., Feb. 1, 2024 CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 1,831,503 shares of its common...

Palatin Announces $10 Million Registered Direct Offering PR Newswire CRANBURY, N.J., Jan. 30, 2024 CRANBURY, N.J. , Jan. 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance...

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 PR Newswire CRANBURY, N.J., Jan. 8, 2024 Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients Interim Analysis Data Readout on Track for 1Q Calendar Year 2024 Topline Results Expected in 2Q Calendar Year 2024 Obesity: Melanocortin...

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million PR Newswire CRANBURY, N.J., Dec. 20, 2023 Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, N.J. , Dec. 20, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on...

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American PR Newswire CRANBURY, N.J., Dec. 18, 2023 CRANBURY, N.J. , Dec. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Palatin's plan...

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire CRANBURY, N.J., Nov. 14, 2023 Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for 1Q Calendar Year 2024 Topline Results Currently Expected in 2Q Calendar Year 2024 Vyleesi ® Gross...

Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023 PR Newswire CRANBURY, N.J., Nov. 9, 2023 CRANBURY, N.J. , Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management...

Palatin Announces Closing of $5 Million Registered Direct Offering PR Newswire CRANBURY, N.J., Oct. 24, 2023 CRANBURY, N.J. , Oct. 24, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 2,358,491 shares of its common...

Palatin Announces $5 Million Registered Direct Offering PR Newswire CRANBURY, N.J., Oct. 23, 2023 CRANBURY, N.J. , Oct. 23, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with an institutional investor for the issuance and sale of an...

Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results PR Newswire CRANBURY, N.J., Oct. 19, 2023 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth over prior quarter; 100% growth over comparable quarter last year $2.1 million in Net Product Revenue 18% growth over prior quarter; 137% growth over comparable quarter last year Prescriptions Dispensed 14% growth over...

Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients PR Newswire CRANBURY, N.J., Oct. 18, 2023 Positive data with Palatin's melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (GLP-1) presented at the Peptide Therapeutics Symposium GLP-1 & MC4R agonist co-administration data shows increased weight loss and greater glucose control above monotherapy Preclinical data and...

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment PR Newswire CRANBURY, N.J., Oct. 16, 2023 Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL8177 Phase 2 ulcerative colitis study CRANBURY, N.J. , Oct. 16, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on...

Palatin Receives Notice of Non-Compliance from NYSE American PR Newswire CRANBURY, N.J., Oct. 13, 2023 Palatin to Deliver Plan of Compliance to NYSE American CRANBURY, N.J. , Oct. 13, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that...

Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update PR Newswire CRANBURY, N.J., Sept. 28, 2023 Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023 Interim Analysis of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye Excellent Patient Safety and Tolerability Product...

Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023 PR Newswire CRANBURY, N.J., Sept. 22, 2023 CRANBURY, N.J. , Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by...